NasdaqGS:STOKBiotechs
Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?
Stoke Therapeutics (STOK) drew investor attention after appointing Thomas McCauley, Ph.D., as Chief Scientific Officer, a move that places an experienced genetic medicines leader at the center of its research and development efforts.
See our latest analysis for Stoke Therapeutics.
Stoke Therapeutics shares recently closed at US$28.81, with a 1 day share price return of 4.08% that partially offsets a 30 day share price decline of 7.06%. The 1 year total shareholder return of 112.31% and 3 year...